gefitinib has been researched along with ipi-145 in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (ipi-145) | Trials (ipi-145) | Recent Studies (post-2010) (ipi-145) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 78 | 14 | 77 |
| Protein | Taxonomy | gefitinib (IC50) | ipi-145 (IC50) |
|---|---|---|---|
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | 0.0147 | |
| Phosphatidylinositol 3-kinase regulatory subunit alpha | Homo sapiens (human) | 1.445 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | 4.0007 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | 0.2855 | |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | 0.0232 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W | 1 |
1 review(s) available for gefitinib and ipi-145
| Article | Year |
|---|---|
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration | 2021 |